A Study of Copanlisib and Ibrutinib in Mantle Cell LymphomaMemorial Sloan Kettering Cancer Center / Bayer
ClinicalTrials.gov Identifier: NCT03877055
Investigators at Memorial Sloan Kettering Cancer Center have opened a Phase I/II clinical trial to test the safety and any positive and negative side effects of combining two study drugs, copanlisib (ALIQOPATM, Bayer) and ibrutinib (IMBRUVICA®, Pharmacyclics, Janssen Biotech), in the treatment of mantle cell lymphoma.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to email@example.com for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.